<DOC>
	<DOCNO>NCT01272193</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate efficacy safety NN5401 ( insulin degludec/insulin aspart ) insulin glargine subject type 2 diabetes Japan . Depending pre-trial oral anti-diabetic drug ( OADs ) , subject continue dose dosing frequency .</brief_summary>
	<brief_title>Comparison NN5401 With Insulin Glargine Insulin Naive Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 6 month HbA1c 7.010.0 % ( inclusive ) central laboratory analysis Body Mass Index ( BMI ) equal 35.0 kg/m^2 Insulin naive subject ongoing treatment 1 oral antidiabetic drug ( OADs ) least 12 week prior randomisation least recommended maintenance dose accord local , approve labelling Allowed : . Previous short term insulin treatment 14 day ; b . Treatment hospitalization gestational diabetes allow period longer 14 day ) Anticipated change concomitant medication know interfere significantly glucose metabolism , systemic corticosteroid , betablockers , mono amino oxidase ( MAO ) inhibitor Use glucagonlike peptide1 ( GLP1 ) receptor agonist , buformine and/or rosiglitazone within last 12 week prior randomisation Cardiovascular disease , within last 6 month prior Visit 1 , define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>